# US 10,864,257 B2 · Method for prevention or treatment of acute and chronic thrombosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,257 B2
- Document ID: US10864257B2
- Status: Granted
- Kind: B2
- Application number: 16/063,534
- Filed: 2016-12-16
- Published: 2019-08-15
- Granted: 2020-12-15
- Earliest claimed: 2015-12-18
- Assignees: Talengen International Limited
- Applicants: Talengen International Limited
- Inventors: Jinan Li
- Web page: https://patentgrep.com/patent/US10864257B2

## CPC

- A61K 38/48: acting on peptide bonds (3.4)
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 25/02: for peripheral neuropathies
- A61P 27/02: Ophthalmic agents
- C12Y 304/21007: Plasmin (3.4.21.7), i.e. fibrinolysin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present invention relates to the use of plasminogen in the dissolution of fresh and old thrombus. Compared with other existing thrombolytic drugs, the plasminogen of the present invention can specifically dissolve thrombus without causing side effects such as bleeding. The drug of the present invention also has the advantages of dissolving both fresh and old thrombus, with a long half-life and controllable thrombolytic strength. Therefore, plasminogen may become a brand-new strategy for dissolving thrombus in vivo.

## Claims

### Claim 1

A method of preventing and/or eliminating an arterial and venous thrombosis in a subject, comprising administering to the subject an effective amount of plasminogen alone.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said thrombus comprises fresh thrombus and old thrombus.

### Claim 3 (depends on 1)

The method of claim 1, wherein the thrombosis is a thrombosis caused by a disease selected from the group consisting of a blood system disease, a circulatory system disease, an autoimmune disease, a metabolic disorder disease and an infectious disease.

### Claim 4 (depends on 1)

The method of claim 1, wherein the thrombosis is a large vascular thrombosis, small vascular thrombosis or microvascular thrombosis, secondary to diabetes.

### Claim 5 (depends on 1)

The method of claim 1, wherein the thrombosis is a thrombosis caused by large and/or small vascular lesions.

### Claim 6

A method of preventing and/or treating thrombosis-related diseases in a subject, comprising administering to the subject an effective amount of plasminogen alone, wherein the plasminogen prevents and/or treats the thrombosis-related disease in the subject by eliminating the thrombus.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the thrombosis-related disease comprises a disease selected from the group consisting of pancreatitis and cirrhosis caused by portal vein thrombosis; renal embolism caused by renal vein thrombosis; systemic sepsis, pulmonary embolism, cerebral thrombosis and deep vein thrombosis caused by internal jugular vein thrombosis; organ infarction caused by arterial or venous thrombosis.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the thrombosis-related disease comprises a disease selected from the group consisting of diabetic nephropathy, diabetic retinopathy, diabetic liver disease, diabetic heart disease, diabetic enteropathy and diabetic neuropathy.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the plasminogen is administered in combination with a therapeutic drug for other diseases accompanying the thrombosis.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the plasminogen is a protein having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with the SEQ ID No.2, 6, 8, 10 or 12 and retaining a plasminogen activity.

### Claim 11 (depends on 7)

The method according to claim 7, wherein the organ infarction caused by arterial or venous thrombosis comprises a disease selected from the group consisting of cerebral infarction, myocardial infarction, thrombotic stroke, atrial fibrillation, unstable angina pectoris, intractable angina pectoris, transient ischemic attack and pulmonary embolism.